Mepolizumab Reduced COPD Exacerbations in Clinical Trials
A pooled analysis revealed that the biologic treatment lowered moderate or severe flare-ups in former and current smokers.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Should medical treatments be prioritized for patients who maintain high-risk lifestyle habits?
On September 28, 2026, researchers published an analysis showing that Mepolizumab reduced moderate or severe COPD exacerbations in both former and current smokers. The study examined data from the METREX, METREO, and MATINEE randomized clinical trials.
Why it matters
This analysis provides critical insight into the efficacy of biologic treatments for COPD patients based on smoking status and blood eosinophil counts. The findings help clarify which patient groups may benefit most from this therapeutic intervention.
The study demonstrated a 19% reduction in moderate/severe exacerbations for former smokers with a blood eosinophil count (BEC) ≥150 cells/µL, rising to 25% at a threshold of ≥300 cells/µL. Current smokers with a BEC ≥150 cells/µL saw a 23% reduction.
The players
GSK
This multinational pharmaceutical and biotechnology company provided the funding for the clinical trials analyzed in the study.
The details
Researchers pooled data from three randomized trials—METREX, METREO, and MATINEE—to evaluate the biologic drug's effectiveness. While former smokers showed significant decreases in hospitalizations and emergency department visits, these improvements were not mirrored in current smokers.
Timeline
September 28, 2026: The analysis of the clinical trial data was published.
The Big Picture
This study updates the therapeutic understanding of Mepolizumab, which is the second biologic approved for COPD.
Patients with COPD may see their physicians place a higher emphasis on blood eosinophil count testing to determine if biologic therapies are appropriate. These results help clarify which smoking-status groups might expect better outcomes from Mepolizumab treatment.
The takeaway
Understanding how inflammatory markers correlate with treatment success is essential for managing chronic respiratory conditions. Patients should consult with their pulmonologist to discuss whether biological therapies are a suitable addition to their current COPD management plan.
Further reading
Learn more about advancements in respiratory care on the Asthma section page.
Live Poll
Should medical treatments be prioritized for patients who maintain high-risk lifestyle habits?
